Global Finance News
22 Jun 2026, 14:24
Eli Lilly Holds Steady as Analysts Remain Positive on Obesity Drug Growth
Eli Lilly (NYSE: LLY) traded roughly flat after receiving supportive analyst commentary from two Wall Street firms. Berenberg raised its price target to $1,135 from $1,050 while maintaining a Hold rating, and Cantor Fitzgerald reiterated its Overweight rating on the stock.
The analyst actions reflect continued confidence in Lilly's long-term growth prospects, driven primarily by the success of its diabetes and obesity treatments. The company remains one of the largest beneficiaries of the rapidly expanding weight-loss drug market, where demand continues to exceed expectations globally.
Investors remain focused on the growth trajectory of Lilly's obesity franchise, including Zepbound, as well as the company's broader pipeline across cardiometabolic diseases, oncology, and neuroscience. Strong demand for GLP-1 therapies has fueled substantial revenue growth and positioned Lilly as one of the pharmaceutical sector's most closely watched companies.
Despite the positive analyst commentary, the stock was little changed. Nevertheless, the higher price target from Berenberg and continued bullish stance from Cantor Fitzgerald indicate that analysts remain optimistic about Lilly's ability to sustain earnings growth as demand for obesity and diabetes treatments continues to expand worldwide.
Eli Lilly (NYSE: LLY) traded roughly flat after receiving supportive analyst commentary from two Wall Street firms. Berenberg raised its price target to $1,135 from $1,050 while maintaining a Hold rating, and Cantor Fitzgerald reiterated its Overweight rating on the stock.
The analyst actions reflect continued confidence in Lilly's long-term growth prospects, driven primarily by the success of its diabetes and obesity treatments. The company remains one of the largest beneficiaries of the rapidly expanding weight-loss drug market, where demand continues to exceed expectations globally.
Investors remain focused on the growth trajectory of Lilly's obesity franchise, including Zepbound, as well as the company's broader pipeline across cardiometabolic diseases, oncology, and neuroscience. Strong demand for GLP-1 therapies has fueled substantial revenue growth and positioned Lilly as one of the pharmaceutical sector's most closely watched companies.
Despite the positive analyst commentary, the stock was little changed. Nevertheless, the higher price target from Berenberg and continued bullish stance from Cantor Fitzgerald indicate that analysts remain optimistic about Lilly's ability to sustain earnings growth as demand for obesity and diabetes treatments continues to expand worldwide.
